DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Joseph Edelman - 1 Davidson Kempner - 1 Roderick Wang - 1
Top related locs:
Moderna San Francisco
Top related orgs:
Biotech - 1 RTW Investments - 1

Search resuls for: "RTW Investments"


7 mentions found


☆ October slammed biotech stocks, and these 3 hedge funds couldn't escape the pain
  + stars: | 2023-11-08 | by ( Bradley Saacks | ) www.businessinsider.com   time to read: +1 min
Biotech hedge funds couldn't escape a tough October, sources told Insider. Managers like Perceptive Advisors and RTW Investments lost more than 9% in just a month's time. While big-name hedge funds were able to avoid some of the market's pain last month, biotech specialists were hit hard. Some funds, including Perceptive Advisors, RTW Investments, and San Francisco-based Redmile Group, had a tough October thanks to pain across the biotech space, according to sources familiar with their performance. The flagship fund at $8 billion Perceptive Advisors, run by billionaire Joseph Edelman, lost 9.5% in the month, bringing its yearly performance to a loss of 8.7%.
Persons: Joseph Edelman, Davidson Kempner, Roderick Wang Organizations: Biotech, RTW Investments Locations: Moderna, San Francisco
☆ Cutera fires CEO, stock tumbles and large investor speaks out
  + stars: | 2023-04-12 | by ( Svea Herbst-Bayliss | ) www.reuters.com   time to read: +2 min
CEO David Mowry and activist investor J. Daniel Plants, who has served on the board for eight years, were terminated for alleged violations of their employment contracts, Cutera said. RTW Investments, Cutera's second biggest investor with a 9.3% stake, called on the company to reinstate Mowry and to hold a special meeting. Market reaction to Mowry's removal "demonstrates the need for the Special Meeting and the lack of confidence in the board," RTW said in a statement. Top Cutera executives, including the chief financial officer, on Tuesday supported Mowry and Plants, arguing the men work well together and had earned their trust. The California-based company, which sells devices including laser treatments for tattoo removal and acne, appointed independent board member Sheila Hopkins as interim CEO.
☆ This biotech founder has a new plan to treat Tourette Syndrome, which affects 200,000 Americans each year
  + stars: | 2023-01-03 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +5 min
Emalex Bioscience is developing a new treatment for Tourette Syndrome. Tourette Syndrome currently has no cure and few treatment options. That's how in 2018 he came to found Emalex Biosciences, a pharmaceutical startup, to test a new drug for Tourette Syndrome. Emalex's drug works in a different way than other Tourette treatmentsIn spite of a tough market for biotech startups, Emalex has managed to raise $250 million from investors in November to develop its Tourette Syndrome drug candidate, called ecopipam. Many of the current approved therapies for Tourette Syndrome target D1 dopamine receptors in the brain.
☆ Only a handful of psychedelics companies have gotten funding from established biotech investors. Here's what they've done right, according to a top VC.
  + stars: | 2022-11-22 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +4 min
RA Capital is one of the few mainstream biotech VCs wading into the psychedelics space. The number of companies touting the benefits of psychedelics for healthcare is rapidly growing, but not all biotech investors are on board yet. Last year RA Capital made two investments into the psychedelics spaceIn 2021, RA made its first investments into the psychedelics space by funding two startups: GH Research and Delix Therapeutics. Dublin, Ireland-based GH Research is one of the only psychedelics companies to have garnered a flurry of interest from mainstream healthcare investors including RA Capital, RTW Investments, and BVF Partners. Lusaris' treatment is designed to be taken sublingually — placed under the tongue — for treatment-resistant depression.
☆ Watch CNBC's full interview with RTW Investment's Dr. Rod Wong
  + stars: | 2022-11-18 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with RTW Investment's Dr. Rod WongDr. Rod Wong, RTW Investments managing partner and CIO, joins the 'Halftime Report' to discuss his thoughts on the biotech sector going into the new year, his investing thesis behind Avidity Biosciences and more.
☆ If we do enter a recession next year, we'll see more of a rotation into health care, says RTW's Wong
  + stars: | 2022-11-18 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailIf we do enter a recession next year, we'll see more of a rotation into health care, says RTW's WongDr. Rod Wong, RTW Investments managing partner and CIO, joins the 'Halftime Report' to discuss his thoughts on the biotech sector going into the new year, his investing thesis behind Avidity Biosciences and more.
☆ Compass Pathways' new CEO says data from his firm's upcoming clinical trial could finally persuade Big Pharma to jump into the psychedelics industry
  + stars: | 2022-11-09 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +3 min
Compass Pathways is set to start its biggest clinical trial yet by the end of this year. But that may soon change as more data around the effectiveness of psychedelics as treatments emerges, according to Kabir Nath, the new CEO of the psychedelics company Compass Pathways. He joined Compass Pathways from the Japanese pharmaceutical company Otsuka in August and led Otsuka's investment into Compass Pathways during the company's $80 million Series B round in 2019. At the time of Otsuka's initial investment into Compass Pathways, the psychedelics industry was relatively new and the potential around such treatments was still not well known. In 2019, the Food and Drug Administration approved a ketamine-based treatment called Spravato for treatment-resistant depression that was developed by Johnson & Johnson's Janssen.
0 next >>
Total: 7